Chronic Lymphocytic Leukemia

Ca2+-flux and cell viability assays using patient-derived BCRs expressed in murine B-cells confirmed reduced ibrutinib efficacy in IGLV3-21R110 cases, especially regarding inhibition of antigen-stimulated signaling. In summary, IGLV3-21R110 is an independent prognostic factor for shorter EFS in early-stage CLL and reduces ibrutinib effectiveness clinically and in vitro.

This retrospective study investigated the relationship between baseline SLC28A3 expression levels, quantified via reverse-transcriptase polymerase chain reaction (qRT-PCR), and the incidence of AIHA in a cohort of CLL patients receiving fludarabine and cyclophosphamide (FC) therapy. These findings suggest that diminished baseline SLC28A3 expression may correlate with an elevated risk of fludarabine-emergent AIHA in CLL patients. Further validation through larger, prospective cohorts is essential to confirm the predictive utility of SLC28A3 expression for optimizing fludarabine-based therapeutic strategies.

P2, N=132, Recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2030 --> Mar 2031 | Trial primary completion date: May 2026 --> May 2027

P3, N=466, Recruiting, Alliance for Clinical Trials in Oncology | Not yet recruiting --> Recruiting | Initiation date: Jan 2026 --> Apr 2026

Imatinib 400 mg daily was initiated but was replaced with dasatinib 100 mg daily because of intolerance. This case highlights the diagnostic complexity of synchronous hematologic malignancies and the importance of comprehensive multimodal evaluation when clinical, morphologic, and laboratory findings are not fully explained by a single diagnosis. Treating the clinically dominant clone while monitoring the second clone may be appropriate when the latter is asymptomatic.

pFAO blockade synergizes with chemotherapy drugs such as venetoclax and cytarabine, enabling exploitation of metabolic vulnerabilities to improve therapeutic outcomes. Integrating solid tumor and leukemia insights, peroxisomes emerge as dynamic lipid-processing organelles coupling FAO, redox buffering, and inter-organelle exchange to cancer persistence. Targeting peroxisome-mediated lipid delivery offers a frontier for overcoming metabolic resilience and therapeutic resistance in leukemia.

P1/2, N=87, Active, not recruiting, Kerry Rogers | Trial completion date: Apr 2026 --> Apr 2027

P2, N=60, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting

P1/2, N=190, Active, not recruiting, ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | Trial completion date: Sep 2026 --> Sep 2027 | Trial primary completion date: Sep 2026 --> Sep 2027

In both settings, alloHCT is feasible and may overcome clinical and biological disease refractoriness. However, its exact benefit and timing remains to be determined.

P1, N=24, Not yet recruiting, Medical College of Wisconsin | Initiation date: May 2026 --> Sep 2026

P1, N=85, Recruiting, Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. | N=50 --> 85